The European Medicines Agency (EMA) has issued a positive opinion on a new, higher dose of semaglutide (7.2 mg) for weight management. Clinical trial data showed that one in three participants with obesity but without diabetes, treated with this 7.2 mg dose, achieved a weight loss of at least 25% over 72 weeks. On average, the weight loss reached 20.7%. The data confirmed that 84% of the weight lost was fat mass, while muscle mass was preserved. This positive opinion means that this new, more potent option of semaglutide, which has shown an average weight loss of 20.7%, could be available for people with obesity early next year, pending final EMA approval. The medication is also currently under review in the United States, the United Kingdom, and several other countries.
